Concise review: Adult mesenchymal stem cells, adult neural crest stem cells, and therapy of neurological pathologies: A state of play

Stem Cells Translational Medicine

Volumn 2, Issue 4, 2013, Pages 284-296

  Neirinckx, Virginie ^a   Coste, Cécile ^a   Rogister, Bernard ^a,b   Wislet Gendebien, Sabine ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adult mesenchymal stem cells; Adult neural crest stem cells; Cellular therapy; Neurological disorders

Indexed keywords

ADULT MESENCHYMAL STEM CELL; ADULT NEURAL CREST STEM CELL; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL LINEAGE; CELL THERAPY; ELECTROPHYSIOLOGY; HUMAN; HUNTINGTON CHOREA; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; NEURAL STEM CELL; NEUROLOGIC DISEASE; PARKINSON DISEASE; REVIEW; SPINAL CORD INJURY; ADULT STEM CELL; ANIMAL; CYTOLOGY; DISEASE MODEL; MESENCHYMAL STROMA CELL; NEURAL CREST; STEM CELL TRANSPLANTATION;

ADULT STEM CELLS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MESENCHYMAL STROMAL CELLS; NERVOUS SYSTEM DISEASES; NEURAL CREST; STEM CELL TRANSPLANTATION;

MLCS; MLOWN;

EID: 84878560627     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0147     Document Type: Review

References (163)

1. Zhao, C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008;132:645–660.
2. Hall, PA, Watt FM. Stem cells: The generation and maintenance of cellular diversity. Development 1989;106:619–633.
3. Thomson, JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived fromhuman blastocysts. Science 1998;282:1145–1147.
4. Takahashi, K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–872.
5. Malgrange, B, Borgs L, Grobarczyk B et al. Using human pluripotent stem cells to untangle neurodegenerative disease mechanisms. Cell Mol Life Sci 2011;68:635–649.
6. Rice, CM, Scolding NJ. Autologous bone marrow stem cells: Properties and advantages. J Neurol Sci 2008;265:59–62.
7. Friedenstein, AJ, Deriglasova UF, Kulagina NN et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2:83–92.
8. Bianco, P, Riminucci M, Kuznetsov S et al. Multipotential cells in the bone marrow stroma: Regulation in the context of organ physiology. Crit Rev Eukaryot Gene Expr 1999;9:159–173.
9. Uccelli, A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726–736.
10. Caplan, AI, Correa D. The MSC: An injury drugstore. Cell Stem Cell 2011;9:11–15.
11. Sanchez-Ramos J, Song S, Cardozo-Pelaez F et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 2000;164:247–256.
12. Woodbury, D, Schwarz EJ, Prockop DJ et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000;61:364–370.
13. Dominici, M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–317.
14. Jiang, Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418: 41–49.
15. Reyes, M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001;98:2615–2625.
16. D’Ippolito G, Diabira S, Howard GA et al. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004;117:2971–2981.
17. D’Ippolito G, Howard GA, Roos BA et al. Isolation and characterization of marrow-isolated adult multilineage inducible (MIAMI) cells. Exp Hematol 2006;34:1608–1610.
18. Pittenger, MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–147.
19. Morrison, SJ, White PM, Zock C et al. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell 1999;96:737–749.
20. Kruger, GM, Mosher JT, Bixby S et al. Neural crest stem cells persist in the adult gut but undergo changes in self-renewal, neuronal subtype potential, and factor responsiveness. Neuron 2002;35:657–669.
21. Toma, JG, McKenzie IA, Bagli D et al. Isolation and characterization of multipotent skin-derived precursors from human skin. STEM CELLS 2005;23:727–737.
22. Hu, YF, Zhang ZJ, Sieber-Blum M. An epidermal neural crest stem cell (EPI-NCSC) molecular signature. STEM CELLS 2006;24:2692–2702.
23. Nagoshi, N, Shibata S, Kubota Y et al. Ontogeny and multipotency of neural crest-derived stem cells in mouse bone marrow, dorsal root ganglia, and whisker pad. Cell Stem Cell 2008;2:392–403.
24. Yoshida, S, Shimmura S, Nagoshi N et al. Isolation of multipotent neural crest-derived stem cells from the adult mouse cornea. STEM CELLS 2006;24:2714–2722.
25. Tomita, Y, Matsumura K, Wakamatsu Y et al. Cardiac neural crest cells contribute to the dormant multipotent stem cell in the mammalian heart. J Cell Biol 2005;170:1135–1146.
26. Arthur, A, Rychkov G, Shi S et al. Adult human dental pulp stem cells differentiate toward functionally active neurons under appropriate environmental cues. STEM CELLS 2008;26: 1787–1795.
27. Widera, D, Zander C, Heidbreder M et al. Adult palatum as a novel source of neural crest-related stem cells. STEM CELLS 2009;27: 1899–1910.
28. Pardal, R, Ortega-Saenz P, Duran R et al. Glia-like stem cells sustain physiologic neurogenesis in the adult mammalian carotid body. Cell 2007;131:364–377.
29. Morikawa, S, Mabuchi Y, Niibe K et al. Development of mesenchymal stem cells partially originate from the neural crest. Biochem Biophys Res Commun 2009;379:1114–1119.
30. Laurent, LC, Ulitsky I, Slavin I et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8: 106–118.
31. Bakhtiari, M, Mansouri K, Sadeghi Y et al. Proliferation and differentiation potential of cryopreserved human skin-derived precursors. Cell Prolif 2012;45:148–157.
32. Delcroix, GJ, Curtis KM, Schiller PC et al. EGF and bFGF pre-treatment enhances neural specification and the response to neuronal commitment of MIAMI cells. Differentiation 2010;80:213–227.
33. Curtis, KM, Gomez LA, Schiller PC. Rac1b regulates NT3-stimulated Mek-Erk signaling, directing marrow-isolated adult multilineage inducible (MIAMI) cells toward an early neuronal phenotype. Mol Cell Neurosci 2012;49: 138–148.
34. Jori, FP, Napolitano MA, Melone MA, et al. Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem 2005;94:645–655.
35. Karaöz E, Demircan PC, Saglam O et al. Human dental pulp stem cells demonstrate better neural and epithelial stem cell properties than bone marrow-derived mesenchymal stem cells. Histochem Cell Biol 2011;136:455–473.
36. Kim, SS, Choi JM, Kim JW, et al. cAMP induces neuronal differentiation of mesenchymal stem cells via activation of extracellular signal-regulated kinase/MAPK. Neuroreport 2005;16:1357–1361.
37. Király M, Porcsalmy B, Pataki A et al. Simultaneous PKC and cAMP activation induces differentiation of human dental pulp stem cells into functionally active neurons. Neurochem Int 2009;55:323–332.
38. Kondo, T, Johnson SA, Yoder MC et al. Sonic hedgehog, retinoic acid synergistically promote sensory fate specification from bone marrow-derived pluripotent stem cells. Proc Natl Acad Sci USA 2005;102:4789–4794.
39. Kondo, T, Matsuoka AJ, Shimomura A et al. Wnt signaling promotes neuronal differentiation from mesenchymal stem cells through activation of Tlx 3. STEM CELLS 2011;29:836–846.
40. Lebonvallet, N, Boulais N, Le Gall C et al. Characterization of neurons from adult human skin-derived precursors in serum-free medium: A PCR array and immunocytological analysis. Exp Dermatol 2012;21:195–200.
41. Lepski, G, Jannes CE, Maciaczyk J et al. Limited Ca2+ and PKA-pathway dependent neurogenic differentiation of human adult mesenchymal stem cells as compared to fetal neuronal stem cells. Exp Cell Res 2010;316: 216–231.
42. Lim, JY, Park SI, Kim SM et al. Neural differentiation of brain-derived neurotrophic factor- expressing human umbilical cord blood-derived mesenchymal stem cells in culture via TrkB-mediated ERK and beta-catenin phosphorylation and following transplantation into the developing brain. Cell Transplant 2011;20: 1855–1866.
43. Lim, JY, Park SI, Oh JH et al. Brain-derived neurotrophic factor stimulates the neural differentiation of human umbilical cord blood-derived mesenchymal stem cells and survival of differentiated cells through MAPK/ERK and PI3K/Akt-dependent signaling pathways. J Neurosci Res 2008;86:2168–2178.
44. Lin, X, Zhang Y, Dong J et al. GM-CSF enhances neural differentiation of bone marrow stromal cells. Neuroreport 2007;18:1113–1117.
45. Liqing, Y, Jia G, Jiqing C et al. Directed differentiation of motor neuron cell-like cells from human adipose-derived stem cells in vitro. Neuroreport 2011;22:370–373.
46. Qi, Y, Zhang F, Song G et al. Cholinergic neuronal differentiation of bone marrow mesenchymal stem cells in rhesus monkeys. Sci China Life Sci 2010;53:573–580.
47. Rooney, GE, Howard L, O’Brien T et al. Elevation of cAMP in mesenchymal stem cells transiently upregulates neural markers rather than inducing neural differentiation. Stem Cells Dev 2009;18:387–398.
48. Scintu, F, Reali C, Pillai R et al. Differentiation of human bone marrow stem cells into cells with a neural phenotype: Diverse effects of two specific treatments. BMC Neurosci 2006;7:14.
49. Tatard, VM, D’Ippolito G, Diabira S et al. Neurotrophin-directed differentiation of human adult marrow stromal cells to dopaminergic- like neurons. Bone 2007;40:360–373.
50. Tio, M, Tan KH, Lee W et al. Roles of dbcAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymallike stem cells. PLoS One 2010;5:e9398.
51. Trzaska, KA, Kuzhikandathil EV, Rameshwar P. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. STEM CELLS 2007;25:2797–2808.
52. Wang, TT, Tio M, Lee W et al. Neural differentiation of mesenchymal-like stem cells from cord blood is mediated by PKA. Biochem Biophys Res Commun 2007;357:1021–1027.
53. Wislet-Gendebien S, Laudet E, Neirinckx V et al. Mesenchymal stem cells and neural crest stem cells from adult bone marrow: Characterization of their surprising similarities and differences. Cell Mol Life Sci 2012;69:2593–2608.
54. Ying, C, Hu W, Cheng B et al. Neural differentiation of rat adipose-derived stem cells in vitro. Cell Mol Neurobiol 2012;32:1255–1263.
55. Zhang, L, Seitz LC, Abramczyk AM et al. cAMP initiates early phase neuron-like morphology changes and late phase neural differentiation in mesenchymal stem cells. Cell Mol Life Sci 2011;68:863–876.
56. Zhang, L, Tan X, Dong C et al. In vitro differentiation of human umbilical cord mesenchymal stem cells (hUCMSCs), derived from Wharton’s jelly, into choline acetyltransferase (ChAT)-positive cells. Int J Dev Neurosci 2012; 30:471–477.
57. Zhang, W, Zeng YS, Wang JM et al. Neurotrophin- 3 improves retinoic acid-induced neural differentiation of skin-derived precursors through a p75NTR-dependent signaling pathway. Neurosci Res 2009;64:170–176.
58. Bi, Y, Gong M, Zhang X et al. Pre-activation of retinoid signaling facilitates neuronal differentiation of mesenchymal stem cells. Dev Growth Differ 2010;52:419–431.
59. Foudah, D, Scuteri A, Redondo J et al. Evaluation of neural markers expression in human mesenchymal stem cells after mesengenic differentiation. Ital J Anat Embryol 2011; 116(suppl):16.
60. Tondreau, T, Lagneaux L, Dejeneffe M et al. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation 2004;72:319–326.
61. Montzka, K, Lassonczyk N, Tschoke B et al. Neural differentiation potential of human bone marrow-derived mesenchymal stromal cells: Misleading marker gene expression. BMC Neurosci 2009;10:16.
62. Carleton, A, Petreanu LT, Lansford R et al. Becoming a new neuron in the adult olfactory bulb. Nat Neurosci 2003;6:507–518.
63. Liu, J, Song L, Jiang C et al. Electrophysiological properties and synaptic function of mesenchymal stem cells during neurogenic differentiation: A mini-review. Int J Artif Organs 2012;35:323–337.
64. Torrente, Y, Polli E. Mesenchymal stem cell transplantation for neurodegenerative diseases. Cell Transplant 2008;17:1103–1113.
65. Joyce, N, Annett G, Wirthlin L et al. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 2010;5: 933–946.
66. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439–1441.
67. Sadan, O, Shemesh N, Cohen Y et al. Adult neurotrophic factor-secreting stem cells: A potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 2009;11:201–204.
68. Caplan, AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98:1076–1084.
69. Crigler, L, Robey RC, Asawachaicharn A et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006;198:54–64.
70. Uccelli, A, Benvenuto F, Laroni A et al. Neuroprotective features of mesenchymal stem cells. Best Pract Res Clin Haematol 2011; 24:59–64.
71. Kan, I, Barhum Y, Melamed E et al. Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice. Stem Cell Rev 2011;7:404–412.
72. Brookmeyer, R, Johnson E, Ziegler-Graham K et al. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 2007; 3:186–191.
73. Kim, JY, Kim DH, Kim JH et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-beta plaques. Cell Death Differ 2012;19:680–691.
74. Lee, JK, Jin HK, Endo S et al. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer’s disease mice by modulation of immune responses. STEM CELLS 2010;28:329–343.
75. Lee, HJ, Lee JK, Lee H et al. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol Aging 2012;33:588–602.
76. Lee, JK, Schuchman EH, Jin HK et al. Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid beta ameliorates Alzheimer’s disease in mice by recruiting bone marrow-induced microglia immune responses. STEM CELLS 2012;30: 1544–1555.
77. Kim, S, KA Chang, J Kim et al. The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer’s disease mice. PLoS One 2012;7:e45757.
78. Li, LY, Li JT, Wu QY et al. Transplantation of NGF-gene-modified bone marrow stromal cells into a rat model of Alzheimer’s disease. J Mol Neurosci 2008;34:157–163.
79. Zhang, P, Zhao G, Kang X et al. Effects of lateral ventricular transplantation of bone marrow-derived mesenchymal stem cells modified with brain-derived neurotrophic factor gene on cognition in a rat model of Alzheimer’s disease. Neural Regen Res 2012;7:245–250.
80. Babaei, P, Soltani Tehrani B, Alizadeh A. Transplanted bone marrow mesenchymal stem cells improve memory in rat models of Alzheimer’s disease. Stem Cells Int 2012;2012: 369417.
81. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5: 525–535.
82. Nussbaum, RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003;348:1356–1364.
83. Hornykiewicz, O. Biochemical aspects of Parkinson’s disease. Neurology 1998;51(suppl 2):S2–S9.
84. Lindvall, O, Brundin P, Widner H et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 1990;247:574–577.
85. Kordower, JH, Freeman TB, Snow BJ et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 1995; 332:1118–1124.
86. Kordower, JH, Goetz CG, Freeman TB et al. Dopaminergic transplants in patients with Parkinson’s disease: Neuroanatomical correlates of clinical recovery. Exp Neurol 1997;144: 41–46.
87. Venkataramana, NK, Kumar SK, Balaraju S et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease. Transl Res 2010;155:62–70.
88. Venkataramana, NK, Pal R, Rao SA et al. Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson’s disease: A pilot clinical study. Stem Cells Int 2012;2012:931902.
89. Fu, YS, Cheng YC, Lin MY et al. Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopaminergic neurons in vitro: Potential therapeutic application for Parkinsonism. STEM CELLS 2006;24:115–124.
90. Wang, J, X Wang, Z Sun et al. Stem cells from human-exfoliated deciduous teeth can differentiate into dopaminergic neuron-like cells. Stem Cells Dev 2010;19:1375–1383.
91. Khoo, ML, Tao H, Meedeniya AC et al. Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents. PLoS One 2011;6: e19025.
92. Suon, S, Yang M, Iacovitti L. Adult human bone marrow stromal spheres express neuronal traits in vitro and in a rat model of Parkinson’s disease. Brain Res 2006;1106:46–51.
93. Levy, YS, Bahat-Stroomza M, Barzilay R et al. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson’s disease. Cytotherapy 2008;10: 340–352.
94. Offen, D, Barhum Y, Levy YS et al. Intrastriatal transplantation of mouse bone marrow- derived stem cells improves motor behavior in a mouse model of Parkinson’s disease. J Neural Transm Suppl 2007;72:133–143.
95. Blandini, F, Cova L, Armentero MT et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 2010;19:203–217.
96. Park, HJ, Shin JY, Lee BR et al. Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a Parkinsonian model. Cell Transplant 2012;21:1629–1640.
97. Chao, YX, He BP, Tay SS. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson’s disease. J Neuroimmunol 2009; 216:39–50.
98. Cova, L, Armentero MT, Zennaro E et al. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson’s disease. Brain Res 2010;1311:12–27.
99. Vassos, E, Panas M, Kladi A et al. Effect of CAG repeat length on psychiatric disorders in Huntington’s disease. J Psychiatr Res 2008;42: 544–549.
100. Landles, C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington’s disease. Fourth in molecular medicine review series. EMBO Rep 2004;5:958–963.
101. Bachoud-Lévi AC, Gaura V, Brugieres P et al. Effect of fetal neural transplants in patients with Huntington’s disease 6 years after surgery: A long-term follow-up study. Lancet Neurol 2006;5:303–309.
102. Bachoud-Lévi AC, Remy P, Nguyen JP et al. Motor and cognitive improvements in patients with Huntington’s disease after neural transplantation. Lancet 2000;356:1975–1979.
103. Lin, YT, Chern Y, Shen CK et al. Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington’s disease mouse models. PLoS One 2011;6:e22924.
104. Snyder, BR, Chiu AM, Prockop DJ et al. Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington’s disease. PLoS One 2010;5:e9347.
105. Rossignol, J, Boyer C, Leveque X et al. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington’s disease: Morphological and behavioral outcomes. Behav Brain Res 2011;217: 369–378.
106. Dey, ND, Bombard MC, Roland BP et al. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington’s disease. Behav Brain Res 2010;214:193–200.
107. Sadan, O, Shemesh N, Barzilay R et al. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington’s disease. Exp Neurol 2012;234:417–427.
108. Ronaghi, M, Erceg S, Moreno-Manzano V et al. Challenges of stem cell therapy for spinal cord injury: Human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells? Stem Cells 2010;28:93–99.
109. Karamouzian, S, Nematollahi-Mahani SN, Nakhaee N et al. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg 2012;114: 935–939.
110. Sieber-Blum M, Schnell L, Grim M et al. Characterization of epidermal neural crest stem cell (EPI-NCSC) grafts in the lesioned spinal cord. Mol Cell Neurosci 2006;32:67–81.
111. Alexanian, AR, Fehlings MG, Zhang Z et al. Transplanted neurally modified bone marrow- derived mesenchymal stem cells promote tissue protection and locomotor recovery in spinal cord injured rats. Neurorehabil Neural Repair 2011;25:873–880.
112. Pedram, MS, Dehghan MM, Soleimani M et al. Transplantation of a combination of autologous neural differentiated and undifferentiated mesenchymal stem cells into injured spinal cord of rats. Spinal Cord 2010;48:457–463.
113. Zhang, W, Yan Q, Zeng YS et al. Implantation of adult bone marrow-derived mesenchymal stem cells transfected with the neurotrophin- 3 gene and pretreated with retinoic acid in completely transected spinal cord. Brain Res 2010;1359:256–271.
114. Schira, J, Gasis M, Estrada V et al. Significant clinical, neuropathological and behavioural recovery from acute spinal cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood. Brain 2012;135:431–446.
115. Park, SI, Lim JY, Jeong CH et al. Human umbilical cord blood-derived mesenchymal stem cell therapy promotes functional recovery of contused rat spinal cord through enhancement of endogenous cell proliferation and oligogenesis. J Biomed Biotechnol 2012; 2012:362473.
116. Sasaki, M, Radtke C, TanAMet al. BDNFhypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci 2009; 29:14932–14941.
117. Quertainmont, R, Cantinieaux D, Botman O et al. Mesenchymal stem cell graft improves recovery after spinal cord injury in adult rats through neurotrophic and pro-angiogenic actions. PLoS One 2012;7:e39500.
118. Biernaskie, J, Sparling JS, Liu J et al. Skinderived precursors generate myelinating Schwann cells that promote remyelination and functional recovery after contusion spinal cord injury. J Neurosci 2007;27:9545–9559.
119. Kamada, T, Koda M, Dezawa M et al. Transplantation of human bone marrow stromal cell-derived Schwann cells reduces cystic cavity and promotes functional recovery after contusion injury of adult rat spinal cord. Neuropathology 2011;31:48–58.
120. Xu, X, Geremia N, Bao F et al. Schwann cell coculture improves the therapeutic effect of bone marrow stromal cells on recovery in spinal cord-injured mice. Cell Transplant 2011; 20:1065–1086.
121. Karussis, D, Karageorgiou C, Vaknin ADembinsky et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010;67:1187–1194.
122. Mazzini, L, Ferrero I, Luparello V et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp Neurol 2010;223:229–237.
123. Kaspar, BK, Mesenchymal stem cells as trojan horses for GDNF delivery in ALS. Mol Ther 2008;16:1905–1906.
124. Suzuki, M, McHugh J, Tork C et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 2008;16:2002–2010.
125. Vercelli, A, Mereuta OM, Garbossa D et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2008;31:395–405.
126. Uccelli, A, Milanese M, Principato MC et al. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol Med 2012;18:794–804.
127. Knippenberg, S, Thau N, Dengler R et al. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon- like peptide 1 prolongs survival in a mouse model of ALS. PLoS One 2012;7:e36857.
128. Boucherie, C, Caumont AS, Maloteaux JM et al. In vitro evidence for impaired neuroprotective capacities of adult mesenchymal stem cells derived from a rat model of familial amyotrophic lateral sclerosis (hSOD1(G93A)). Exp Neurol 2008;212:557–561.
129. Koh, SH, Baik W, Noh MY et al. The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate. Exp Neurol 2012; 233:472–480.
130. Cho, GW, Noh MY, Kim HY et al. Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev 2010;19: 1035–1042.
131. Choi, MR, Kim HY, Park JY et al. Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 2010;472:94–98.
132. Kim, H, Kim HY, Choi MR et al. Dosedependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1–G93A ALS mice. Neurosci Lett 2010;468:190–194.
133. Donnan, GA, Fisher M, MacleodMet al. Stroke. Lancet 2008;371:1612–1623.
134. Bang, OY, Lee JS, Lee PH et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005;57:874–882.
135. Bhasin, A, Padma Srivastava MV, Mohanty S et al. Stem cell therapy: A clinical trial of stroke. Clin Neurol Neurosurg (in press).
136. Honmou, O, Houkin K, Matsunaga T et al. Intravenous administration of auto serumexpanded autologous mesenchymal stem cells in stroke. Brain 2011;134:1790–1807.
137. Lee, JS, Hong JM, Moon GJ et al. A longterm follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. STEM CELLS 2010; 28:1099–1106.
138. Mora-Lee S, Sirerol-Piquer MS, Gutierrez- Perez M et al. Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice. PLoS One 2012;7:e43683.
139. Fatar, M, Stroick M, Griebe M et al. Lipoaspirate- derived adult mesenchymal stem cells improve functional outcome during intracerebral hemorrhage by proliferation of endogenous progenitor cells stem cells in intracerebral hemorrhages. Neurosci Lett 2008;443: 174–178.
140. Leong, WK, Henshall TL, Arthur A et al. Human adult dental pulp stem cells enhance poststroke functional recovery through nonneural replacement mechanisms. STEM CELLS TRANSL MED 2012;1:177–187.
141. Liu, N, Zhang Y, Fan L et al. Effects of transplantation with bone marrow-derived mesenchymal stem cells modified by Survivin on experimental stroke in rats. J Transl Med 2011;9:105.
142. Wakabayashi, K, Nagai A, Sheikh AM et al. Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model. J Neurosci Res 2010;88:1017–1025.
143. Lin, YC, Ko TL, Shih YH et al. Human umbilical mesenchymal stem cells promote recovery after ischemic stroke. Stroke 2011;42: 2045–2053.
144. Kurozumi, K, Nakamura K, Tamiya T et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther 2005;11:96–104.
145. Yang, C, Zhou L, Gao X et al. Neuroprotective effects of bone marrow stem cells overexpressing glial cell line-derived neurotrophic factor on rats with intracerebral hemorrhage and neurons exposed to hypoxia/reoxygenation. Neurosurgery 2011;68:691–704.
146. Yang, KL, Lee JT, Pang CY et al. Human adipose-derived stem cells for the treatment of intracerebral hemorrhage in rats via femoral intravenous injection. Cell Mol Biol Lett 2012; 17:376–392.
147. Lim, JY, Jeong CH, Jun JA et al. Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia. Stem Cell Res Ther 2011;2:38.
148. Tsai, LK, Wang Z, Munasinghe J et al. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 2011;42:2932–2939.
149. Steiner, B, Roch M, Holtkamp N et al. Systemically administered human bone marrow- derived mesenchymal stem home into peripheral organs but do not induce neuroprotective effects in the MCAo-mouse model for cerebral ischemia. Neurosci Lett 2012;513:25–30.
150. Freedman, MS, Bar-Or A, Atkins HL et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group. Mult Scler 2010;16:503–510.
151. Mallam, E, Kemp K, Wilkins A et al. Characterization of in vitro expanded bone marrow- derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler 2010; 16:909–918.
152. Connick, P, Kolappan M, Crawley C et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol 2012;11:150–156.
153. Yamout, B, Hourani R, Salti H et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol 2010;227: 185–189.
154. Gerdoni, E, Gallo B, Casazza S et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007;61:219–227.
155. Kassis, I, Grigoriadis N, Gowda-Kurkalli B et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008;65:753–761.
156. Zhang, J, Li Y, Chen J et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005;195:16–26.
157. Liu, R, Zhang Z, Lu Z et al. Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. Stem Cells Dev 2012 (in press).
158. Zhang, J, Li Y, Lu M et al. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J Neurosci Res 2006;84:587–595.
159. Harris, VK, Yan QJ, Vyshkina T et al. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci 2012;313:167–177.
160. Bai, L, Lennon DP, Eaton V et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009;57:1192–1203.
161. Bai, L, Lennon DP, Caplan AI et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci 2012;15:862–870.
162. Uccelli, A, Morando S, Bonanno S et al. Mesenchymal stem cells for multiple sclerosis: Does neural differentiation really matter? Curr Stem Cell Res Ther 2011;6:69–72.
163. Uccelli, A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011;10:649–656.